Vedolizumab, a monoclonal immunoglobulin (Ig)G4 antibody, has a favorable safety profile in nonpregnant and nonlactating patients.1 The data on the safety of vedolizumab in reproduction is limited,2,3 with currently none available in lactating mothers.